Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Opiant Pharmaceuticals revenue
Opiant Pharmaceuticals's revenue is $40.5 million.
What is Opiant Pharmaceuticals's revenue?
- Opiant Pharmaceuticals's revenue growth from 2015 to 2020 is 2,514.18%.
- Opiant Pharmaceuticals has 30 employees, and the revenue per employee ratio is $1,350,660.
- Opiant Pharmaceuticals peak revenue was $40.5M in 2020.
- Opiant Pharmaceuticals annual revenue for 2019 was 14.0M, 18.87% growth from 2018.
- Opiant Pharmaceuticals annual revenue for 2020 was 40.5M, 189.8% growth from 2019.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Opiant Pharmaceuticals historical revenue
Opiant Pharmaceuticals annual revenue
Opiant Pharmaceuticals annual revenue over time
| Fiscal year / year | Opiant Pharmaceuticals revenue |
|---|---|
| 2015 | $1.6M |
| 2016 | $9.9M |
| 2017 | $18.4M |
| 2018 | $11.8M |
| 2019 | $14.0M |
| 2020 | $40.5M |
How accurately did Opiant Pharmaceuticals' revenue projections match actual performance?
Opiant Pharmaceuticals annual growth
Opiant Pharmaceuticals saw the greatest revenue growth in 2016, when revenue increased by 538.55%.
Opiant Pharmaceuticals had the lowest revenue growth in 2018, when revenue changed by -36.23%.
Opiant Pharmaceuticals annual growth rate over time
| Year | Opiant Pharmaceuticals growth |
|---|---|
| 2016 | 539%↑ |
| 2017 | 86%↑ |
| 2018 | -36%↓ |
| 2019 | 19%↑ |
| 2020 | 190%↑ |
Opiant Pharmaceuticals jobs nearby
Do you work at Opiant Pharmaceuticals?
Is Opiant Pharmaceuticals transparent about its revenue structure?
Opiant Pharmaceuticals financial information
| CEO | Roger Crystal M.D., Mba |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 30 |
| Date Founded | 2009 |
| Headquarters | Santa Monica, California |
| Number of Locations | 2 |
| Revenue | $40.5M |
| Net Income | $11,593,050 |
| Tax Rate | -0.0% |
| Total Assets | $40,280,509 |
| Ticker | OPNT |
Opiant Pharmaceuticals jobs you might like
Opiant Pharmaceuticals financing
Opiant Pharmaceuticals received early financing of $50.0M on 2020-10-12.
| Series | Round size | Date |
|---|---|---|
| Debt Financing | $50M | 10/2020 |
| Grant | $2M | 01/2022 |
Opiant Pharmaceuticals investors
| Investors | Security type |
|---|---|
| Pontifax | Debt Financing |
| Biomedical Advanced Research and Development Authority (BARDA) | Grant |
Opiant Pharmaceuticals competitors
Opiant Pharmaceuticals's top competitor, Moderna, earned an annual revenue of $3.2B.
Opiant Pharmaceuticals's smallest competitor is Edgewise Therapeutics with revenue of $30.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Recro Pharma Inc. | - | $94.6M | 255 | - |
| Sollis Therapeutics | - | $130,000 | 7 | - |
| aTyr Pharma | - | $235,000 | 44 | - |
| Amicus Therapeutics | - | $528.3M | 508 | - |
| Moderna | - | $3.2B | 2,500 | - |
| BridgeBio | - | $221.9M | 396 | - |
| Edgewise Therapeutics | - | $30,000 | 45 | - |
| Arrakis Therapeutics | - | $1.0M | 78 | - |
Opiant Pharmaceuticals revenue FAQs
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Most in demand jobs
Zippia gives an in-depth look into the details of Opiant Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Opiant Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Opiant Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Opiant Pharmaceuticals. The data presented on this page does not represent the view of Opiant Pharmaceuticals and its employees or that of Zippia.
Opiant Pharmaceuticals may also be known as or be related to OPIANT PHARMACEUTICALS INC., Opiant Pharmaceuticals, Opiant Pharmaceuticals Inc and Opiant Pharmaceuticals, Inc.